108
Views
5
CrossRef citations to date
0
Altmetric
Original Research

Joint Effect of Hepatic Steatosis and Alanine Aminotransferase Within the Normal Range on Incident Ischemic Heart Disease: A Prospective Study in Koreans

, & ORCID Icon
Pages 513-523 | Published online: 22 Mar 2021

References

  • Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.2843126707365
  • Kang SY, Kim YJ, Park HS. Trends in the prevalence of non-alcoholic fatty liver disease and its future predictions in Korean men, 1998–2035. J Clin Med. 2020;9(8):2626. doi:10.3390/jcm9082626
  • Cho HJ, Hwang S, Park JI, et al. Improvement of nonalcoholic fatty liver disease reduces the risk of type 2 diabetes mellitus. Gut Liver. 2019;13(4):440–449. doi:10.5009/gnl1838230970431
  • Reginato E, Pippi R, Aiello C, et al. Effect of short term intensive lifestyle intervention on hepatic steatosis indexes in adults with obesity and/or type 2 diabetes. J Clin Med. 2019;8(6):851. doi:10.3390/jcm8060851
  • Li AA, Ahmed A, Kim D. Extrahepatic manifestations of nonalcoholic fatty liver disease. Gut Liver. 2020;14(2):168–178. doi:10.5009/gnl1906931195434
  • Gastaldelli A, Kozakova M, Højlund K, et al. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. Hepatology. 2009;49(5):1537–1544. doi:10.1002/hep.2284519291789
  • Targher G, Zoppini G, Day CP. Risk of all-cause and cardiovascular mortality in patients with chronic liver disease. Gut. 2011;60(11):1602–1603. doi:10.1136/gut.2010.23065621159890
  • Westerbacka J, Corner A, Tiikkainen M, et al. Women and men have similar amounts of liver and intra-abdominal fat, despite more subcutaneous fat in women: implications for sex differences in markers of cardiovascular risk. Diabetologia. 2004;47(8):1360–1369. doi:10.1007/s00125-004-1460-115309287
  • Vozarova B, Stefan N, Lindsay RS, et al. High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002;51(6):1889–1895. doi:10.2337/diabetes.51.6.188912031978
  • Schindhelm RK, Diamant M, Bakker SJ, et al. Liver alanine aminotransferase, insulin resistance and endothelial dysfunction in normotriglyceridaemic subjects with type 2 diabetes mellitus. Eur J Clin Invest. 2005;35(6):369–374. doi:10.1111/j.1365-2362.2005.01502.x15948897
  • Cho EJ, Han K, Lee SP, Shin DW, Yu SJ. Liver enzyme variability and risk of heart disease and mortality: a nationwide population-based study. Liver Int. 2020;40(6):1292–1302. doi:10.1111/liv.1443232153096
  • Pacifico L, Ferraro F, Bonci E, Anania C, Romaggioli S, Chiesa C. Upper limit of normal for alanine aminotransferase: Quo vadis? Clin Chim Acta. 2013;422:29–39. doi:10.1016/j.cca.2013.03.03023566931
  • Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98(5):960–967. doi:10.1111/j.1572-0241.2003.07486.x12809815
  • Kotronen A, Westerbacka J, Bergholm R, Pietilainen KH, Yki-Jarvinen H. Liver fat in the metabolic syndrome. J Clin Endocrinol Metab. 2007;92(9):3490–3497. doi:10.1210/jc.2007-048217595248
  • Jang DK, Lee JK, Lee JK, Kim YH. Independent association of physical activity with nonalcoholic fatty liver disease and alanine aminotransferase levels. J Clin Med. 2019;8(7):1013. doi:10.3390/jcm8071013
  • Kang HS, Um SH, Seo YS, et al. Healthy range for serum ALT and the clinical significance of “unhealthy” normal ALT levels in the Korean population. J Gastroenterol Hepatol. 2011;26(2):292–299. doi:10.1111/j.1440-1746.2010.06481.x21261719
  • Chen CH, Nien CK, Yang CC, Yeh YH. Association between nonalcoholic fatty liver disease and coronary artery calcification. Dig Dis Sci. 2010;55(6):1752–1760. doi:10.1007/s10620-009-0935-919688595
  • Wang CC, Lin SK, Tseng YF, et al. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2009;24(8):1411–1416. doi:10.1111/j.1440-1746.2009.05872.x19702910
  • Schindhelm RK, Dekker JM, Nijpels G, et al. Alanine aminotransferase predicts coronary heart disease events: a 10-year follow-up of the Hoorn Study. Atherosclerosis. 2007;191(2):391–396. doi:10.1016/j.atherosclerosis.2006.04.00616682043
  • Targher G, Marra F, Marchesini G. Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon? Diabetologia. 2008;51(11):1947–1953. doi:10.1007/s00125-008-1135-418762907
  • Kim Y, Chang Y, Cho YK, Ahn J, Shin H, Ryu S. Metabolically healthy versus unhealthy obesity and risk of fibrosis progression in non-alcoholic fatty liver disease. Liver Int. 2019;39(10):1884–1894. doi:10.1111/liv.1418431226232
  • Tobari M, Hashimoto E. Characteristic features of nonalcoholic fatty liver disease in Japan with a focus on the roles of age, sex and body mass index. Gut Liver. 2020;14(5):537–545. doi:10.5009/gnl1923631887811
  • Schindhelm RK, Diamant M, Dekker JM, Tushuizen ME, Teerlink T, Heine RJ. Alanine aminotransferase as a marker of non‐alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes Metab Res Rev. 2006;22(6):437–443. doi:10.1002/dmrr.66616832839
  • Malakouti M, Kataria A, Ali SK, Schenker S. Elevated liver enzymes in asymptomatic patients - what should i do? J Clin Transl Hepatol. 2017;5(4):394–403. doi:10.14218/JCTH.2017.0002729226106
  • Fraser A, Ebrahim S, Smith GD, Lawlor DA. A comparison of associations of alanine aminotransferase and gamma-glutamyltransferase with fasting glucose, fasting insulin, and glycated hemoglobin in women with and without diabetes. Hepatology. 2007;46(1):158–165. doi:10.1002/hep.2166717596883
  • Hanley AJ, Wagenknecht LE, Festa A, D’Agostino RB, Haffner SM. Alanine aminotransferase and directly measured insulin sensitivity in a multiethnic cohort: the insulin resistance atherosclerosis study. Diabetes Care. 2007;30(7):1819–1827. doi:10.2337/dc07-008617429060
  • Gaggini M, Morelli M, Buzzigoli E, DeFronzo RA, Bugianesi E, Gastaldelli A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013;5(5):1544–1560. doi:10.3390/nu505154423666091
  • Challa TD, Wueest S, Lucchini FC, et al. Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis. EMBO Mol Med. 2019;11(10):e10124. doi:10.15252/emmm.20181012431595673
  • Yilmaz Y. Is non‐alcoholic fatty liver disease a spectrum, or are steatosis and non‐alcoholic steatohepatitis distinct conditions? Aliment Pharmacol Thera. 2012;36(9):815–823. doi:10.1111/apt.12046
  • Wajngot A, Chandramouli V, Schumann WC, et al. Quantitative contributions of gluconeogenesis to glucose production during fasting in type 2 diabetes mellitus. Metab Clin Exp. 2001;50(1):47–52. doi:10.1053/meta.2001.1942211172474
  • Kim BK, Han KH, Ahn SH. “Normal” range of alanine aminotransferase levels for Asian population. J Gastroenterol Hepatol. 2011;26(2):219–220. doi:10.1111/j.1440-1746.2010.06603.x21261710
  • Chang Y, Ryu S, Sung E, Jang Y. Higher concentrations of alanine aminotransferase within the reference interval predict nonalcoholic fatty liver disease. Clin Chem. 2007;53(4):686–692. doi:10.1373/clinchem.2006.08125717272484
  • Kim J, Yoon S, Kim LY, Kim DS. Towards actualizing the value potential of Korea Health Insurance Review and Assessment (HIRA) data as a resource for health research: strengths, limitations, applications, and strategies for optimal use of HIRA data. J Kor Med Sci. 2017;32(5):718–728. doi:10.3346/jkms.2017.32.5.718
  • Fraser CG, Cummings ST, Wilkinson SP, et al. Biological variability of 26 clinical chemistry analytes in elderly people. Clin Chem. 1989;35(5):783–786. doi:10.1093/clinchem/35.5.7832720971
  • Mathiesen UL, Franzén LE, Aselius H, et al. Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis. 2002;34(7):516–522. doi:10.1016/S1590-8658(02)80111-612236486
  • Cheung CL, Lam KS, Wong IC, Cheung BM. Non-invasive score identifies ultrasonography-diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA. BMC Med. 2014;12(1):154. doi:10.1186/s12916-014-0154-x25204761